In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pressure BioSciences Inc.

www.pressurebiosciences.com

Latest From Pressure BioSciences Inc.

Deals Shaping The Medical Industry, May 2016

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, Pharmaceuticals, and Research/Analytical Supplies – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in April 2016.

BioPharmaceutical Medical Device

Deal Statistics Quarterly, Q2 2004

Statistical review compiled from our Strategic Transactions database including financings by type (IPO, private placement etc.); financings by sector (surgical equipment, implantable devices, etc.); alliances by therapeutic category (cardiovascular, orthopedic, etc.); alliances by industry segment (biomaterials, monitoring equipment, etc. ); for three separate industries: medical devices, in vitro diagnostics, and pharmaceuticals/biotechnology.
BioPharmaceutical Medical Device

Shrinking Discovery

The theory that smaller is better--as it is has been in the computer industry--is now driving enthusiasm for nanotechnology, a term that refers to the process of manipulating materials at atomic scale. New players are crowding under this hot rubric, including many working at not nearly so small a scale. Drug discovery methods are among the most compelling near-term nano-applications, but start-ups face challenges like those met by micro-scale pioneers Affymetrix and Caliper. Firms must show they can physically create systems they describe, and that teeny discovery methods actually matter for bench scientists. Business models in this emerging sector reflect the difficulties of harnessing novel science in ways that will satisfy drugmakers who've become extra-tough customers under pressure to deliver commercial results in a shifting, financially depressed market. Some start-ups are working on a fee-for-service basis, on specific projects that address customers' immediate needs. Others are deliberately doing development work on their own, gathering data to attract partnerships that may prove all the more rewarding because of their measured starts.
BioPharmaceutical Strategy

Panacos Pharmaceuticals Ltd.

Panacos Pharmaceuticals Inc. is pursuing parallel strategies to discover novel antiviral drugs and vaccines, with a particular focus on HIV's growing resistance to approved therapeutics. Its lead candidates are synthetic versions of compounds discovered through its natural products screening platform. The company is also searching for orally available inhibitors of viral fusion-the initial step in viral infection.
BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
  • In Vitro Diagnostics
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Boston Biomedica Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Pressure BioSciences Inc.
  • Senior Management
  • Richard T Schumacher, Pres. & CEO
    Edmund Ting, SVP, Engineering
    Nathan P Lawrence, PhD, VP, Marketing & BD
    Alexander Lazarev, PhD, VP, R&D
  • Contact Info
  • Pressure BioSciences Inc.
    Phone: (508) 230-1828
    14 Norfolk Avenue South
    Easton, MA 02375
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register